AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer

Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.